Aida Arcas

Oct 31, 2023 | clarivate.com | Aida Arcas

What do the years 2001, 2007, 2014, and 2022 have in common? These years witnessed significant troughs in pharma financing, a drop in the capital markets, and an IPO window that remained firmly shut. In short, the biotech bubble had burst. Cream will always rise to the top and there will always be a buyer for quality assets, whether therapeutics, platforms, or technology.

Oct 25, 2023 | clarivate.com | Aida Arcas

What the White House’s initial list of drugs to be reviewed under the Inflation Reduction Act tells us about how the law could impact biopharma going forwardWith the naming of the first 10 drugs selected for price negotiations, the Inflation Reduction Act has moved into a new phase that promises to reshape pharmaceutical companies and other organizations.

Jul 24, 2023 | nature.com | Aina Maria Mas |Enrique Goñi |Aida Arcas |Luisa Statello |Dipika Gupta |Jernej Ule | +3 more

Cell lines, growth conditions, and culture treatmentsHCT116 cells (CCL-247) were cultured in RPMI-1640 (GIBCO), and U2OS cells (HTB-96) in DMEM (GIBCO), all mediums supplemented with 10% fetal bovine serum (GIBCO) and 1x penicillin/streptomycin (Lonza), and maintained at 37 ˚C and 5% CO2.

Mar 7, 2023 | biorxiv.org | Aina Maria Mas |Enrique Goñi |Aida Arcas |Luisa Statello

AbstractCells must coordinate the activation of thousands of replication origins dispersed throughout their genome. Active transcription is known to favor the formation of mammalian origins, although the role that RNA plays in this process remains unclear. We show that the ORC1 subunit of the human Origin Recognition Complex interacts with RNAs transcribed from genes with origins in their transcription start sites (TSSs), displaying a positive correlation between RNA binding and origin activity.